Allogene Q3 net loss narrows to $41.4 mln

Reuters11-07

Allogene Q3 net loss narrows to $41.4 mln

Overview

Allogene Q3 net loss narrowed to $41.4 mln from $66.3 mln
Company advances pivotal Phase 2 ALPHA3 trial for LBCL treatment
Phase 1 RESOLUTION trial with ALLO-329 in autoimmune diseases is enrolling

Outlook

ALLO-329 proof-of-concept data anticipated in 1H 2026
Cash runway projected to extend into 2H 2027

Result Drivers

OPERATING EXPENSES - Declined to $44.9 mln from $71.7 mln a year ago, with R&D expenses down to $31.2 mln and G&A expenses falling to $13.7 mln

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.19
Q3 Net Income		-$41.40 mln
Q3 Basic EPS		-$0.19
Q3 Income From Operations		-$44.90 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Allogene Therapeutics Inc is $7.50, about 85.2% above its November 5 closing price of $1.11

Press Release: ID:nGNX9JKkLZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581049195?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 06:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581049195","market":"us","top_or_hot":-1,"title":"Allogene Q3 net loss narrows to $41.4 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Allogene Q3 net loss narrows to $41.4 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Allogene Q3 net loss narrowed to $41.4 mln from $66.3 mln</p></li><li><p>Company advances pivotal Phase 2 ALPHA3 trial for LBCL treatment</p></li><li><p>Phase 1 RESOLUTION trial with ALLO-329 in autoimmune diseases is enrolling</p></li></ul><p><span>Outlook</span></p><ul><li><p>ALLO-329 proof-of-concept data anticipated in 1H 2026</p></li><li><p>Cash runway projected to extend into 2H 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>OPERATING EXPENSES - Declined to $44.9 mln from $71.7 mln a year ago, with R&amp;D expenses down to $31.2 mln and G&amp;A expenses falling to $13.7 mln</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.19</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$41.40 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.19</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$44.90 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $7.50, about 85.2% above its November 5 closing price of $1.11</p></li></ul><p>Press Release: <span>ID:nGNX9JKkLZ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allogene Q3 net loss narrows to $41.4 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllogene Q3 net loss narrows to $41.4 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 06:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Allogene Q3 net loss narrows to $41.4 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Allogene Q3 net loss narrowed to $41.4 mln from $66.3 mln</p></li><li><p>Company advances pivotal Phase 2 ALPHA3 trial for LBCL treatment</p></li><li><p>Phase 1 RESOLUTION trial with ALLO-329 in autoimmune diseases is enrolling</p></li></ul><p><span>Outlook</span></p><ul><li><p>ALLO-329 proof-of-concept data anticipated in 1H 2026</p></li><li><p>Cash runway projected to extend into 2H 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>OPERATING EXPENSES - Declined to $44.9 mln from $71.7 mln a year ago, with R&amp;D expenses down to $31.2 mln and G&amp;A expenses falling to $13.7 mln</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.19</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$41.40 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.19</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$44.90 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $7.50, about 85.2% above its November 5 closing price of $1.11</p></li></ul><p>Press Release: <span>ID:nGNX9JKkLZ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1LM:1","article_id":"2581049195","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581049195","pubTimestamp":1762468005,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Allogene Q3 net loss narrows to $41.4 mlnOverviewAllogene Q3 net loss narrowed to $41.4 mln from $66.3 mlnCompany advances pivotal Phase 2 ALPHA3 trial for LBCL treatmentPhase 1 RESOLUTION trial with ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","ALLO":"Allogene Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Allogene第三季度净亏损收窄至4140万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":0.9},"content_text":"Allogene Q3 net loss narrows to $41.4 mlnOverviewAllogene Q3 net loss narrowed to $41.4 mln from $66.3 mlnCompany advances pivotal Phase 2 ALPHA3 trial for LBCL treatmentPhase 1 RESOLUTION trial with ALLO-329 in autoimmune diseases is enrollingOutlookALLO-329 proof-of-concept data anticipated in 1H 2026Cash runway projected to extend into 2H 2027Result DriversOPERATING EXPENSES - Declined to $44.9 mln from $71.7 mln a year ago, with R&D expenses down to $31.2 mln and G&A expenses falling to $13.7 mlnKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.19Q3 Net Income-$41.40 mlnQ3 Basic EPS-$0.19Q3 Income From Operations-$44.90 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Allogene Therapeutics Inc is $7.50, about 85.2% above its November 5 closing price of $1.11Press Release: ID:nGNX9JKkLZFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581049195","isCrawlerRequest":true}